Product Details
Additional Information
| Product Name | Opdivo 10 mg/mL 4 mL SDV 1/Ea |
| Application | Immunotherapy (PD-1 Inhibitor) |
| Generic Drug Name | Nivolumab |
| Mechanism of Action | Blocks PD-1 receptor, enhancing T-cell activity against tumor cells |
| Strength | 10 mg/mL |
| Volume | 4 mL |
| Type | Intravenous |
| Administration Instructions | Infuse over 30 to 60 minutes; must be diluted before administration; do not shake |
| Half-life | ~25 days |
| Common Adverse Effects | Fatigue, rash, pruritus, diarrhea, nausea, musculoskeletal pain, decreased appetite |
| Serious Risks | Pneumonitis, colitis, hepatitis, nephritis, myocarditis, endocrinopathies |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F); protect from light; do not freeze |
| Indications | Non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, Hodgkin lymphoma, MSI-H colorectal cancer, head and neck squamous cell carcinoma, urothelial carcinoma |
Description
Opdivo (Nivolumab 10 mg/mL) Injection is a monoclonal antibody classified as a programmed death-1 (PD-1) inhibitor, indicated for the treatment of various cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, Hodgkin lymphoma, and microsatellite instability-high (MSI-H) colorectal cancer. It functions by blocking PD-1 receptor activity, enhancing the immune system’s ability to recognize and attack cancer cells.
Opdivo is supplied as a 10 mg/mL intravenous solution in a 4 mL single-dose vial. The dosing schedule depends on the specific cancer type and treatment regimen, typically administered every 2 to 4 weeks as an intravenous infusion over 30 to 60 minutes. It is often used as monotherapy or in combination with other immune checkpoint inhibitors, such as ipilimumab, to improve therapeutic outcomes.
Common adverse effects include fatigue, rash, pruritus, nausea, diarrhea, musculoskeletal pain, and decreased appetite. Serious immune-mediated toxicities involve pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, and myocarditis, requiring careful monitoring and corticosteroid intervention if severe toxicity occurs.
Frequently Asked Questions (FAQs)
The cost of OPDIVO 10MG/ML 4ML SDV 1/EA is $available for registerd members only
OPDIVO 10MG/ML 4ML SDV 1/EA is manufactured by Bristol Myers.
You can purchase OPDIVO 10MG/ML 4ML SDV 1/EA on our website at https://pkd.pipelinemedical.com/product/detail/opdivo-10mg-ml-4ml-sdv-1-ea-422394